Predictive Oncology, Inc. ( POAI ) shares are trading higher on Tuesday after the company announced it developed predictive models to target various cancer types.

The Details: The models were developed using 21 unique compounds from the University of Michigan's Natural Products Discovery Core, which were tested for their effectiveness against cancers such as breast, colon and ovarian.

The collaboration used Predictive Oncology's ( POAI ) machine learning platform to select and test the compounds. Three compounds showed strong tumor-fighting effects across multiple cancer types, even outperforming a standard drug. A fourth was effective against both ovarian and colon cancers, while three others produced the best results against breast, colon and ovarian cancers.

“Demonstrating that these natural compounds have such strong anti-tumor activity against several human tumor types strongly supports further investigations into these compounds and additional compounds, especially when considering that these results were achieved by including only about 1% of the available NPDC library,” said NPDC Director Dr. Ashu Tripathi.

See Also: What’s Going On With Trump Media & Technology Group Stock Tuesday?

POAI Price Action: At the time of writing, Predictive Oncology ( POAI ) shares are trading 66.8% higher at $1.86, according to data from Benzinga Pro.

Image: via Shutterstock